Trial Profile
A Phase I Trial of Sorafenib and LBH589 in the Treatment of Advanced HCC.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Dec 2020
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 10 Dec 2020 Status changed from recruiting to discontinued.
- 22 Jan 2009 New trial record.